{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:46:46Z","timestamp":1793137606438,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010429","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000}}],"reference-count":69,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010429.pub2","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T10:04:56Z","timestamp":1457690696000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment for osteoporosis in people with \u00df-thalassaemia"],"prefix":"10.1002","author":[{"given":"Amit","family":"Bhardwaj","sequence":"first","affiliation":[{"name":"Newcastle University Medicine Malaysia, No 1; Jalan Sarjana 1 Kota Ilmu, Educity@iskandar Nusajaya Johor Malaysia 79200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Mon Min","family":"Swe","sequence":"additional","affiliation":[{"name":"Perdana University, Royal College of Surgeons in Ireland School of Medicine (PU-RCSI); Blok D, Level 1, MAEPS Building, MARDI Complex, Jalan MAEPS Perdana Serdang Selangor Darul Ehsan Malaysia 43400"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal K","family":"Sinha","sequence":"additional","affiliation":[{"name":"Melaka-Manipal Medical College (MMMC); Department of Orthopaedics; Jalan Batu Hampar Bukit Baru Melaka Melaka Malaysia 75150"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeyinwa","family":"Osunkwo","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Service, Emory University School of Medicine; Comprehensive Sickle Cell Program; 1405 Clifton Road, NE Atlanta Georgia USA GA 30322"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"issue":"21","key":"10.1002\/14651858.CD010429.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"Abstract no: 42","DOI":"10.1182\/blood.V116.21.4282.4282","article-title":"Neridronate (NE) for the treatment of osteoporosis in patients with beta-thalassemia: results from an Italian multicenter randomized, open label, phase II trial [abstract]","volume":"116","author":"Forni","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","article-title":"Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized parallel-arm, open-label study","volume":"158","author":"Forni","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3945\/ajcn.112.049221","article-title":"Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial","volume":"98","author":"Fung","year":"2013","journal-title":"American Journal of Clinical Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD010429.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s001980200087","article-title":"Bisphosphonates in the treatment of thalassemia-induced osteoporosis","volume":"13","author":"Morabito","year":"2002","journal-title":"Osteoporosis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010429.pub2-BIB0005|cit5","first-page":"S205","article-title":"Effect of pamidronate on bone remodeling in adult patients with beta-thalassemia major and osteoporosis [abstract]","volume":"5","author":"Voskaridou","year":"2003","journal-title":"Bone"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0006|cit6","unstructured":"Voskaridou E Terpos E Spina G Palermos J Rahemtulla A Loutradi A Pamidronate is an effective treatment for osteoporosis in patients with thalassemia major [abstract] Proceedings of the 8th Congress of the European Hematology Association; 2003 June 12-15; Lyon, France 2003 Abstract no: 1"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"Abstract no: 10","DOI":"10.1182\/blood.V120.21.1029.1029","article-title":"The effect of vitamin D supplementation on calcium excretion in thalassemia [abstract]","volume":"120","author":"Balachandar","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000204084","article-title":"Effects of calcitonin therapy on osteoporosis in patients","volume":"93","author":"Canatan","year":"1995","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00223-006-0314-x","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia","volume":"79","author":"Gilfillan","year":"2006","journal-title":"Calcified Tissue International"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02917329","article-title":"A study on children's condition thalassemia using neutron activation analysis and other techniques","volume":"43","author":"Krishnan","year":"1994","journal-title":"Biological Trace Elements Research"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00277-006-0136-y","article-title":"Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial","volume":"85","author":"Otrock","year":"2006","journal-title":"Annals of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010429.pub2-BIB0012|cit12","first-page":"10","article-title":"Intravenous zoledronic acid treatment in thalassaemia-induced osteoporosis: results of a phase two clinical trial [abstract]","volume":"91","author":"Taher","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00774-003-0435-5","article-title":"Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis","volume":"21","author":"Pennisi","year":"2003","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0014|cit14","first-page":"144","article-title":"Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major","volume":"6 Suppl 1","author":"Skordis","year":"2008","journal-title":"Pediatric Endocrinology Reviews: PER"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0015|cit15","first-page":"342","article-title":"Zoledronic acid increases bone mineral density in patients with thalassemia intermedia-induced osteoporosis despite the continuous bone marrow expansion [abstract]","volume":"92 Suppl 1","author":"Voskaridou","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"Abstract no: 38","DOI":"10.1182\/blood.V110.11.3813.3813","article-title":"Zoledronic acid increases bone mineral density in patients with thalassemia intermedia-induced osteoporosis regardless of the incessant bone marrow expansion [abstract]","volume":"110","author":"Voskaridou","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000114869","article-title":"Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis","volume":"119","author":"Voskaridou","year":"2008","journal-title":"Acta Haematologica"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub2-BIB0018|cit18","first-page":"1193","article-title":"Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0019|cit19","first-page":"Abstract no: 27","article-title":"Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow- up of a randomized, placebo-controlled trial","volume":"11","author":"Voskaridou","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"Abstract no: 38","DOI":"10.1182\/blood.V112.11.3889.3889","article-title":"Serum Dickkopf-1 is increased and correlates with bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration [abstract]","volume":"112","author":"Voskaridou","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0021|cit21","first-page":"63","article-title":"Serum sclerostin correlates with bone mineral density in patients with thalassemia major and osteoporosis; implications into the management of thalassemia-related osteoporosis [abstract]","volume":"96","author":"Voskaridou","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD010429.pub2-BIB0022|cit22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1010.1010","article-title":"High circulating levels of sclerostin correlate with bone mineral density in patients with thalassemia and osteoporosis: the role of the WNT signaling in the pathogenesis of bone loss in thalassemia [abstract]","volume":"116","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0023|cit23","first-page":"173","article-title":"TIMP-1 balance effect on elevated MMP-9 in patients with thalassemia major and osteoporosis","volume":"96","author":"Voskaridou","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3324\/haematol.2008.000893","article-title":"Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration","volume":"94","author":"Voskaridou","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD010429.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"Abstract no: 36","DOI":"10.1182\/blood.V106.11.3656.3656","article-title":"Zoledronic acid is an effective treatment for osteoporosis in patients with thalassemia major: results of a randomized, placebo-controlled, trial [abstract]","volume":"106","author":"Voskaridou","year":"2005","journal-title":"Blood"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD010429.pub2-BIB0026|cit26","first-page":"S248, Abstract","article-title":"Bone mass and bone turnover in women with thalassemia major related osteoporosis: Effects of strontium ranelate [abstract]","volume":"26","author":"Catalano","year":"2015","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0027|cit27","unstructured":"Gurkan EG Evran M Tuli A Baslamisli F Kilinc Y Effect of zoledronic acid on the osteoporosis of thalassemia [abstract] Proceedings of the 10th Congress of the European Hematology Association; 2005 June 2-5; Stockholm International Fairs, Sweden 2005 Abstract no: 0164"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub2-BIB0028|cit28","first-page":"657","article-title":"New\u00a0approaches\u00a0to\u00a0pharmacological treatment\u00a0of\u00a0osteoporosis","volume":"81","author":"Akesson","year":"2003","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jcp.47.7.657","article-title":"Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one or desferrioxamine","volume":"47","author":"Al-Refaie","year":"1994","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.1995.tb01876.x","article-title":"The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches","volume":"42","author":"Anapliotou\u00a0ML","year":"1995","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1749-6632.1998.tb10482.x","article-title":"Global epidemiology of hemoglobin disorders","volume":"850","author":"Angastiniotis","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.2830240203","article-title":"Effect of zinc supplementation on linear growth in thalassaemia","volume":"24","author":"Arcasoy","year":"1987","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with \u03b2-thalassaemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormones"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub2-BIB0034|cit34","first-page":"196","article-title":"Fractures in transfusion dependent beta thalassemia- an Indian study","volume":"42","author":"Basanagoudar","year":"2001","journal-title":"Singapore Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e18028","DOI":"10.5812\/ircmj.18028","article-title":"Hydroxyurea treatment in transfusion dependent thalassaemia patients","volume":"16","author":"Bordbar","year":"2014","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2007.06654.x","article-title":"Modern treatment of thalassaemia intermedia","volume":"138","author":"Borgna-Pignatti","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000204084","article-title":"Effects of calcitonin therapy on osteoporosis in patients with thalassemia","volume":"93","author":"Canatan\u00a0D","year":"1995","journal-title":"Acta Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormone"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01955263","article-title":"Growth and development in thalassaemia major patients with bone lesion due to desferrioxamine","volume":"155","author":"Sanctis","year":"1996","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0040|cit40","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/096228020101000502","article-title":"Statistical\u00a0methods\u00a0for the\u00a0meta-analysis\u00a0of\u00a0cluster\u00a0randomization\u00a0trials","volume":"10","author":"Donner","year":"2001","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0043|cit43","first-page":"65","article-title":"Mechanisms of action of the bisphosphonates","volume":"57 Suppl 1","author":"Fleisch\u00a0H","year":"1997","journal-title":"Medicina (Buenos Aires)"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassaemia","volume":"21","author":"Galanello","year":"2010","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03345587","article-title":"Bisphosphonates in the treatment of thalassemia-associated osteoporosis","volume":"31","author":"Gaudio","year":"2008","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0046|cit46","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0047|cit47","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] Available from www.cochrane-handbook.org 2011"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub2-BIB0048|cit48","first-page":"975","article-title":"High incidence of\u00a0osteoporosis\u00a0in\u00a0thalassaemia\u00a0major","volume":"11","author":"Jensen\u00a0CE","year":"1998","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.1998.01108.x","article-title":"High prevalence of low bone mass in thalassaemia major","volume":"103","author":"Jensen","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"5A","key":"10.1002\/14651858.CD010429.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/0002-9343(93)90380-8","article-title":"Hormone replacement therapy for prevention and treatment of\u00a0osteoporosis","volume":"95","author":"Lindsay","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub2-BIB0051|cit51","first-page":"297","article-title":"Zinc and copper status in children with beta-thalassemia major","volume":"20","author":"Mahyar","year":"2010","journal-title":"Iranian Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/03630269.2011.598985","article-title":"Clinicopathological and radiological study of Egyptian \u03b2-thalassemia intermedia and \u03b2-thalassemia major patients: relation to complications and response to therapy","volume":"35","author":"Mokhtar","year":"2011","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2004.04871.x","article-title":"Treatment of beta-thalassaemia-associated\u00a0osteoporosis\u00a0with zoledronic acid","volume":"125","author":"Perifanis\u00a0V","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0054|cit54","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010429.pub2-BIB0055|cit55","first-page":"3773","article-title":"Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients","volume":"11","author":"Ruggiero","year":"1998","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0056|cit56","first-page":"167","article-title":"Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment","volume":"11","author":"Sanctis","year":"2013","journal-title":"Pediatric Endocrinology Reviews (PER)"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03191.x","article-title":"Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites","volume":"69","author":"Scacchi","year":"2008","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD010429.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/08880010701533702","article-title":"Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major","volume":"24","author":"Shamshirsaz","year":"2007","journal-title":"Pediatric Hematology and Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1359\/jbmr.1997.12.6.869","article-title":"Regulation of osteoclast function","volume":"12","author":"Suda","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"issue":"10","key":"10.1002\/14651858.CD010429.pub2-BIB0060|cit60","first-page":"817","article-title":"Prevalence of fractures among Thais with thalassaemia syndromes","volume":"51","author":"Sutipornpalangkul","year":"2010","journal-title":"Singapore Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009415.pub2","article-title":"Zinc supplements for treating thalassaemia and sickle cell disease","author":"Swe","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1749-6632.1998.tb10491.x","article-title":"The morbidity of bone disease in thalassaemia","volume":"850","author":"Vichinsky","year":"1998","journal-title":"Annals New York Academy of Sciences"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1196\/annals.1345.003","article-title":"Changing patterns of thalassemia worldwide","volume":"1054","author":"Vichinsky","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.10.001","article-title":"Prevalence of fractures among the thalassemia syndromes in North America","volume":"38","author":"Vogiatzi","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","article-title":"New insight into the pathophysiology and management of osteoporosis in patient with beta thalassaemia","volume":"127","author":"Voskaridou","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0066|cit66","first-page":"581","article-title":"The Thalassemias","volume-title":"Williams Hematology","author":"Weatherall","year":"1995"},{"key":"10.1002\/14651858.CD010429.pub2-BIB0067|cit67","unstructured":"World Health Organisation Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843 http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_843.pdf"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2141.1998.01107.x","article-title":"Bone Disease in \u03b2-thalassaemia Major","volume":"103","author":"Wonke","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0037-1963(01)90029-0","article-title":"Clinical management of beta-thalassemia major","volume":"38","author":"Wonke","year":"2001","journal-title":"Seminars in Hematology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010429.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010429.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:44:02Z","timestamp":1628549042000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010429.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010429.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010429.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}